Introduction
Oxidative stress represents one of the most fundamental and early pathogenic mechanisms in neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease (HD)1Oxidative stress in Alzheimer's disease (2023)Open reference2Oxidative stress in Parkinson's disease (2023)Open reference. Defined as an imbalance between the production of reactive oxygen species (ROS) and the cellular antioxidant defense capacity, oxidative stress contributes to neuronal dysfunction and death through multiple pathways, including lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dysfunction3Reactive oxygen species in neurodegeneration (2024)Open reference4Oxidative damage mechanisms in neurodegeneration (2023)Open reference. The brain is particularly vulnerable to oxidative damage due to its high metabolic rate, elevated oxygen consumption, and relatively limited antioxidant capacity compared to other organs5Brain oxidative stress in neurodegeneration (2023)Open reference.
The role of oxidative stress in neurodegeneration has evolved from being considered a secondary consequence of other pathological processes to a primary driver of disease initiation and progression6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference. Evidence demonstrates that oxidative damage precedes the appearance of classic pathological hallmarks such as amyloid-beta plaques, neurofibrillary tangles, or alpha-synuclein inclusions, suggesting that oxidative stress may be an early upstream event that initiates or accelerates downstream pathological cascades7Oxidative stress precedes pathology in AD (2024)Open reference8Oxidative damage in early AD (2023)Open reference. This understanding has significant therapeutic implications, as antioxidant therapies could potentially prevent or slow disease progression if administered early in the disease process.
Sources of Reactive Oxygen Species in the Brain
Mitochondrial Electron Transport Chain
The mitochondria represent the primary cellular source of ROS, generating superoxide anion (O2•-) as a byproduct of normal oxidative phosphorylation9Murphy, Mitochondrial ROS production (2023)Open reference10Mitochondria and oxidative stress in neurons (2024)Open reference. Complex I (NADH dehydrogenase) and Complex III (ubiquinol-cytochrome c reductase) of the electron transport chain (ETC) are the main sites of superoxide production during normal respiration2Oxidative stress in Parkinson's disease (2023)Open reference0. Under physiological conditions, approximately 0.2-2% of oxygen consumed by mitochondria is partially reduced to form superoxide, which is then converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD)2Oxidative stress in Parkinson's disease (2023)Open reference1.
In neurodegenerative diseases, mitochondrial dysfunction leads to increased ROS production through multiple mechanisms2Oxidative stress in Parkinson's disease (2023)Open reference2. Mutations in mitochondrial DNA (mtDNA) accumulate with age and are enhanced in AD and PD, leading to defective ETC components that produce more superoxide2Oxidative stress in Parkinson's disease (2023)Open reference3. Impaired complex activities (particularly Complex I in PD and Complex IV in AD) create electron leak and enhance ROS generation2Oxidative stress in Parkinson's disease (2023)Open reference4. Additionally, damaged mitochondria have reduced efficiency of the ETC, further increasing electron leak and ROS production in a vicious cycle of oxidative damage and mitochondrial dysfunction2Oxidative stress in Parkinson's disease (2023)Open reference5.
NADPH Oxidases (NOX)
NADPH oxidases represent another major source of ROS in the brain, particularly in glial cells and neurons2Oxidative stress in Parkinson's disease (2023)Open reference62Oxidative stress in Parkinson's disease (2023)Open reference7. Originally discovered in phagocytic cells as a host defense mechanism, NOX enzymes are now known to be expressed in neurons and glia where they produce ROS in response to various stimuli2Oxidative stress in Parkinson's disease (2023)Open reference8. The NOX2 isoform is highly expressed in microglia and is activated by amyloid-beta, leading to ROS production that contributes to neuroinflammation and neuronal damage in AD2Oxidative stress in Parkinson's disease (2023)Open reference9.
In Parkinson’s disease, NOX activation in dopaminergic neurons contributes to oxidative stress and cell death3Reactive oxygen species in neurodegeneration (2024)Open reference0. The NOX1 isoform is expressed in neurons and can be activated by various pathological stimuli, including aggregated alpha-synuclein3Reactive oxygen species in neurodegeneration (2024)Open reference1. NOX-derived ROS can also activate inflammatory signaling pathways, creating a feed-forward loop between oxidative stress and neuroinflammation that amplifies neuronal damage3Reactive oxygen species in neurodegeneration (2024)Open reference2.
Metal Ion Homeostasis and Fenton Chemistry
Brain metal ion dyshomeostasis, particularly of iron, copper, and zinc, contributes significantly to oxidative stress in neurodegeneration3Reactive oxygen species in neurodegeneration (2024)Open reference33Reactive oxygen species in neurodegeneration (2024)Open reference4. Transition metals can catalyze the production of highly reactive hydroxyl radicals (•OH) through the Fenton reaction, where reduced metals (Fe2+ or Cu+) react with hydrogen peroxide to produce •OH and the oxidized metal form3Reactive oxygen species in neurodegeneration (2024)Open reference5. This reaction is particularly damaging because •OH is the most reactive ROS and attacks lipids, proteins, and DNA with near diffusion-limited rate constants.
In Alzheimer’s disease, elevated iron and copper levels colocalize with amyloid-beta plaques, and the interaction between these metals and A beta promotes ROS generation3Reactive oxygen species in neurodegeneration (2024)Open reference6. Iron accumulation in the substantia nigra is a characteristic finding in Parkinson’s disease and is believed to contribute to the selective vulnerability of dopaminergic neurons3Reactive oxygen species in neurodegeneration (2024)Open reference7. The iron-binding protein ferritin is elevated in neurodegenerative diseases, reflecting a cellular response to increased iron and oxidative stress3Reactive oxygen species in neurodegeneration (2024)Open reference8.
Inflammatory Cell-Derived ROS
Activated microglia and infiltrating immune cells produce ROS through NOX enzymes and other mechanisms, contributing to oxidative stress in the neurodegenerative environment3Reactive oxygen species in neurodegeneration (2024)Open reference94Oxidative damage mechanisms in neurodegeneration (2023)Open reference0. In AD, amyloid-beta activates microglia via pattern recognition receptors (including TLRs and CD36), leading to ROS production that exacerbates neuronal damage4Oxidative damage mechanisms in neurodegeneration (2023)Open reference1. The chronic inflammatory state in neurodegenerative diseases creates a sustained source of ROS from activated glial cells.
In Parkinson’s disease, microglia are activated by neuromelanin (released from dying dopaminergic neurons) and alpha-synuclein aggregates, leading to sustained ROS production that contributes to progressive neuronal loss4Oxidative damage mechanisms in neurodegeneration (2023)Open reference2. This neuroinflammatory component of oxidative stress creates spatial amplification of damage beyond the initial site of pathology.
Antioxidant Defense Systems
Enzymatic Antioxidants
Cells possess multiple enzymatic antioxidant systems to neutralize ROS and maintain redox homeostasis4Oxidative damage mechanisms in neurodegeneration (2023)Open reference34Oxidative damage mechanisms in neurodegeneration (2023)Open reference4. Superoxide dismutase (SOD) converts superoxide to hydrogen peroxide, with three isoforms: cytosolic Cu/Zn-SOD (SOD1), mitochondrial Mn-SOD (SOD2), and extracellular SOD (SOD3)4Oxidative damage mechanisms in neurodegeneration (2023)Open reference5. Mutations in SOD1 are responsible for approximately 20% of familial ALS cases, demonstrating the critical importance of this enzyme for neuronal survival4Oxidative damage mechanisms in neurodegeneration (2023)Open reference6.
Catalase and glutathione peroxidases (GPx) convert hydrogen peroxide to water4Oxidative damage mechanisms in neurodegeneration (2023)Open reference7. Catalase is particularly important in peroxisomes, while GPx uses reduced glutathione (GSH) as an electron donor to reduce peroxides, producing oxidized glutathione (GSSG)4Oxidative damage mechanisms in neurodegeneration (2023)Open reference8. The glutathione system is crucial for neuronal antioxidant defense, and GSH levels are reduced in AD, PD, and other neurodegenerative conditions4Oxidative damage mechanisms in neurodegeneration (2023)Open reference9. Glutathione reductase recycles GSSG back to GSH, maintaining the reduced glutathione pool necessary for continuous antioxidant function5Brain oxidative stress in neurodegeneration (2023)Open reference0.
Non-Enzymatic Antioxidants
Non-enzymatic antioxidants provide additional protection against oxidative damage5Brain oxidative stress in neurodegeneration (2023)Open reference1. Vitamin E (alpha-tocopherol) is the most important lipid-soluble antioxidant, protecting cell membranes from lipid peroxidation5Brain oxidative stress in neurodegeneration (2023)Open reference2. Vitamin E levels are reduced in AD and PD brains, and supplementation has been explored as a therapeutic strategy with mixed results5Brain oxidative stress in neurodegeneration (2023)Open reference3. Vitamin C (ascorbic acid) is the major water-soluble antioxidant in the brain and can regenerate oxidized vitamin E5Brain oxidative stress in neurodegeneration (2023)Open reference4.
Coenzyme Q10 (ubiquinone) is a mitochondrial antioxidant that also functions in electron transport5Brain oxidative stress in neurodegeneration (2023)Open reference5. Reduced CoQ10 levels have been reported in PD and AD, and CoQ10 supplementation has shown some promise in clinical trials for neurodegenerative diseases5Brain oxidative stress in neurodegeneration (2023)Open reference6. The carotenoid antioxidants (lutein, zeaxanthin, beta-carotene, beta-cryptoxanthin) and the flavonoid class of plant-derived antioxidants also contribute to neuronal antioxidant defense5Brain oxidative stress in neurodegeneration (2023)Open reference7.
Oxidative Damage in Neurodegeneration
Lipid Peroxidation
Lipid peroxidation is particularly damaging in the brain due to its high lipid content5Brain oxidative stress in neurodegeneration (2023)Open reference85Brain oxidative stress in neurodegeneration (2023)Open reference9. Membrane phospholipids undergo radical chain reactions initiated by •OH, producing lipid hydroperoxides (LOOH) and reactive aldehydes such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA)6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference0. These lipid peroxidation products form covalent adducts with proteins, further amplifying cellular damage and interfering with normal protein function6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference1.
In Alzheimer’s disease, lipid peroxidation is elevated in vulnerable brain regions and correlates with disease severity6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference2. 4-HNE modifies key proteins involved in energy metabolism, antioxidant defense, and tau phosphorylation, contributing to multiple aspects of the pathogenic cascade6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference3. Lipid peroxidation products also activate stress-sensitive signaling pathways and can trigger apoptosis6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference4. In Parkinson’s disease, lipid peroxidation is elevated in the substantia nigra and is believed to contribute to dopaminergic neuron vulnerability6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference5.
Protein Oxidation
Oxidative modification of proteins alters their structure and function, contributing to neuronal dysfunction6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference66Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference7. Carbonylation (introduction of carbonyl groups into amino acid side chains) is a irreversible oxidative modification that marks proteins for degradation but can also impair function when it occurs in essential proteins6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference8. Protein carbonyls are elevated in AD, PD, and other neurodegenerative conditions, and the pattern of carbonylation reveals which proteins are most affected6Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)Open reference9.
Specific proteins damaged by oxidation in neurodegeneration include: mitochondrial enzymes (leading to energy failure), antioxidant enzymes (reducing cellular defense), and signaling proteins (disrupting normal cellular communication)7Oxidative stress precedes pathology in AD (2024)Open reference0. The oxidation of enzymes such as glutamine synthetase in AD impairs astrocytic function and glutamate cycling, contributing to excitotoxicity7Oxidative stress precedes pathology in AD (2024)Open reference1.
DNA Damage
Oxidative DNA damage accumulates in neurodegenerative diseases through multiple mechanisms7Oxidative stress precedes pathology in AD (2024)Open reference27Oxidative stress precedes pathology in AD (2024)Open reference3. The base excision repair (BER) pathway handles most oxidative DNA lesions, including 8-oxoguanine (8-oxoG), the most common oxidative DNA damage product7Oxidative stress precedes pathology in AD (2024)Open reference4. 8-oxoG mispairs with adenine during DNA replication, causing G:C to T:A transversion mutations if not repaired.
In AD, oxidative DNA damage is elevated in neurons and correlates with the earliest cognitive changes7Oxidative stress precedes pathology in AD (2024)Open reference5. The base excision repair capacity is reduced in AD, impairing the removal of oxidative lesions and leading to their accumulation7Oxidative stress precedes pathology in AD (2024)Open reference6. In PD, mitochondrial DNA (mtDNA) accumulates mutations at a higher rate than nuclear DNA due to proximity to ROS sources and limited repair capacity, contributing to the progressive decline of mitochondrial function7Oxidative stress precedes pathology in AD (2024)Open reference7.
Mitochondrial Dysfunction
Mitochondrial dysfunction and oxidative stress form a vicious cycle in neurodegeneration7Oxidative stress precedes pathology in AD (2024)Open reference87Oxidative stress precedes pathology in AD (2024)Open reference9. ROS damage mitochondrial components including ETC proteins, cardiolipin, and mtDNA, impairing mitochondrial function and increasing ROS production8Oxidative damage in early AD (2023)Open reference0. Damaged mitochondria have reduced ATP production, leading to energy failure and impaired cellular homeostasis8Oxidative damage in early AD (2023)Open reference1.
The permeability transition pore (PTP) is a mitochondrial channel whose opening is promoted by oxidative stress, leading to mitochondrial membrane potential loss, release of pro-apoptotic factors (cytochrome c, AIF), and activation of the intrinsic apoptotic pathway8Oxidative damage in early AD (2023)Open reference2. This mechanism is believed to be important in the progressive neuronal loss that characterizes neurodegenerative diseases8Oxidative damage in early AD (2023)Open reference3.
Therapeutic Implications
Antioxidant Therapy Approaches
The recognition of oxidative stress as a key pathogenic mechanism has driven the development of antioxidant-based therapeutic strategies8Oxidative damage in early AD (2023)Open reference48Oxidative damage in early AD (2023)Open reference5. Direct antioxidants such as vitamin E, vitamin C, and CoQ10 have been tested in clinical trials for AD and PD with mixed results8Oxidative damage in early AD (2023)Open reference6. The failure of many antioxidant trials may reflect: (1) insufficient antioxidant potency; (2) inadequate brain penetration; (3) timing of intervention (too late in disease course); or (4) complex pro-oxidant effects of some antioxidants in specific contexts8Oxidative damage in early AD (2023)Open reference7.
More sophisticated approaches target specific sources of ROS rather than global antioxidant supplementation8Oxidative damage in early AD (2023)Open reference8. NOX inhibitors (e.g., apocynin, GKT137831) are being developed for neurodegenerative diseases based on the role of NOX in ROS production and neuroinflammation8Oxidative damage in early AD (2023)Open reference9. Mitochondria-targeted antioxidants such as MitoQ (coenzyme Q10 attached to a triphenylphosphonium cation for mitochondrial accumulation) and SS-31 (a peptide that targets cardiolipin) have shown promise in preclinical models9Murphy, Mitochondrial ROS production (2023)Open reference0.
Modulating Metal Ion Homeostasis
Given the role of metal dyshomeostasis in oxidative stress, strategies to restore normal metal handling have been explored9Murphy, Mitochondrial ROS production (2023)Open reference1. Chelation therapy to remove excess iron has been tested in PD and AD, with some positive results but also concerns about removing essential metal ions9Murphy, Mitochondrial ROS production (2023)Open reference2. Metal-protein-attenuating compounds (MPACs) such as clioquinol bind to metal ions while preserving normal metal homeostasis and have shown benefit in clinical trials for AD9Murphy, Mitochondrial ROS production (2023)Open reference3.
Enhancing Endogenous Antioxidant Defenses
Rather than providing exogenous antioxidants, approaches to boost the cell’s own antioxidant systems may be more effective9Murphy, Mitochondrial ROS production (2023)Open reference4. Nrf2 (nuclear factor erythroid 2-related factor 2) is the master regulator of antioxidant gene expression, activating transcription of genes encoding phase II detoxifying enzymes, antioxidant proteins, and glutathione synthesis enzymes9Murphy, Mitochondrial ROS production (2023)Open reference5. Nrf2 activators such as dimethyl fumarate (approved for multiple sclerosis) are being tested in neurodegenerative diseases9Murphy, Mitochondrial ROS production (2023)Open reference6.
Conclusion
Oxidative stress is a central mechanism in the pathogenesis of neurodegenerative diseases, acting both as an early trigger of pathology and as a contributor to disease progression through multiple downstream effects. The brain’s vulnerability to oxidative damage, combined with the multiple sources of ROS and the limited regenerative capacity of neurons, creates a perfect storm that drives progressive neuronal dysfunction and death. Understanding the specific sources and effects of oxidative stress in each disease context is enabling the development of more targeted therapeutic approaches. While simple antioxidant supplementation has largely failed as a disease-modifying therapy, more sophisticated strategies targeting specific ROS sources, metal homeostasis, and endogenous antioxidant pathways offer promise for future development.
Therapeutic Strategies
Antioxidant-Based Therapies
The therapeutic potential of antioxidants in neurodegenerative diseases has been extensively studied, though clinical translation has proven challenging9Murphy, Mitochondrial ROS production (2023)Open reference7. Direct antioxidants such as vitamin E and vitamin C have shown mixed results in clinical trials, likely due to their limited ability to target the specific ROS/RNS species and cellular compartments involved in neurodegeneration9Murphy, Mitochondrial ROS production (2023)Open reference8.
More promising approaches include mitochondria-targeted antioxidants such as MitoQ (mitoquinone) and SS-31 (elamipretide), which concentrate in mitochondria and directly scavenge ROS at the site of production9Murphy, Mitochondrial ROS production (2023)Open reference9. These compounds have shown neuroprotective effects in preclinical models of AD and PD.
Nrf2 Activation
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is the master regulator of antioxidant response genes10Mitochondria and oxidative stress in neurons (2024)Open reference0. Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1. Upon oxidative stress, Nrf2 translocates to the nucleus and activates expression of antioxidant and cytoprotective genes including HO-1, NQO1, and GCLM.
Pharmacological Nrf2 activators including bardoxolone methyl and dimethyl fumarate have been investigated in neurodegenerative diseases10Mitochondria and oxidative stress in neurons (2024)Open reference1. However, the systemic effects of Nrf2 activation raise concerns about potential adverse effects on cell proliferation.
Endogenous Antioxidant Enhancement
Enhancing the activity of endogenous antioxidant systems represents an attractive therapeutic strategy10Mitochondria and oxidative stress in neurons (2024)Open reference2. Compounds that increase GSH levels, such as N-acetylcysteine (NAC) and glutathione analogs, have shown promise in preclinical models. Similarly, increasing SOD or catalase activity through gene therapy or small molecules may provide neuroprotective effects.
Biomarkers of Oxidative Stress
Peripheral Markers
Oxidative stress biomarkers in blood and cerebrospinal fluid can provide insights into disease status and progression10Mitochondria and oxidative stress in neurons (2024)Open reference3. Common peripheral markers include 8-OHdG (8-hydroxy-2’-deoxyguanosine) for DNA oxidation, 4-HNE (4-hydroxynonenal) for lipid peroxidation, and protein carbonyls for protein oxidation. Elevated levels of these markers have been documented in AD, PD, and related disorders.
Imaging Markers
Advanced imaging techniques allow in vivo visualization of oxidative stress in the brain10Mitochondria and oxidative stress in neurons (2024)Open reference4.磁共振光谱学 (MRS) can detect altered levels of antioxidant metabolites. Additionally, PET radiotracers targeting oxidative stress markers are under development.
Clinical Utility
The clinical utility of oxidative stress biomarkers remains an area of active investigation10Mitochondria and oxidative stress in neurons (2024)Open reference5. While elevated oxidative stress markers are consistently observed in neurodegenerative diseases, their specificity is limited. Biomarker panels that combine oxidative stress markers with other disease-specific markers may improve diagnostic accuracy.
Future Directions
Precision Antioxidant Therapy
Given the complexity of oxidative stress in neurodegeneration, precision approaches that target specific pathways may be more effective10Mitochondria and oxidative stress in neurons (2024)Open reference6. This includes developing antioxidants that target particular ROS/RNS species, cellular compartments, or disease-specific mechanisms.
Combination Therapies
Combining antioxidants with other disease-modifying therapies may provide synergistic benefits10Mitochondria and oxidative stress in neurons (2024)Open reference7. For example, combining antioxidants with anti-amyloid or anti-tau therapies could address multiple pathological hallmarks simultaneously.
Prevention Strategies
Lifestyle interventions that reduce oxidative stress may delay neurodegeneration10Mitochondria and oxidative stress in neurons (2024)Open reference8. Regular physical exercise, caloric restriction, and diets rich in antioxidants have been associated with reduced neurodegenerative disease risk and cognitive preservation in aging.
Pathway & Interaction Diagram
Interactive diagram showing Oxidative Stress’s key relationships in the SciDEX knowledge graph (15 connections shown).
flowchart TD
Oxidative_Stress["Oxidative Stress"]
HSPA1A(["HSPA1A"])
ERK1(["ERK1"])
HSP70(["HSP70"])
ACTB(["ACTB"])
OPTN(["OPTN"])
ULK1(["ULK1"])
SMCR8(["SMCR8"])
CALCOCO2(["CALCOCO2"])
LC3(["LC3"])
BECN1(["BECN1"])
C9ORF72(["C9ORF72"])
NBR1(["NBR1"])
G3BP1(["G3BP1"])
TOLLIP(["TOLLIP"])
HSPA1A -.->|"inhibits"| Oxidative_Stress
ERK1 -->|"activates"| Oxidative_Stress
HSPA1A -->|"activates"| Oxidative_Stress
HSP70 -->|"activates"| Oxidative_Stress
ACTB -->|"regulates"| Oxidative_Stress
OPTN -->|"regulates"| Oxidative_Stress
ULK1 -->|"regulates"| Oxidative_Stress
SMCR8 -->|"regulates"| Oxidative_Stress
CALCOCO2 -->|"regulates"| Oxidative_Stress
LC3 -->|"regulates"| Oxidative_Stress
BECN1 -->|"regulates"| Oxidative_Stress
C9ORF72 -->|"regulates"| Oxidative_Stress
NBR1 -->|"regulates"| Oxidative_Stress
G3BP1 -->|"regulates"| Oxidative_Stress
TOLLIP -->|"regulates"| Oxidative_Stress
style Oxidative_Stress fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0See Also
External Links
References
- Oxidative stress in Alzheimer's disease (2023)
- Oxidative stress in Parkinson's disease (2023)
- Reactive oxygen species in neurodegeneration (2024)
- Oxidative damage mechanisms in neurodegeneration (2023)
- Brain oxidative stress in neurodegeneration (2023)
- Gandhi & Abramov, Oxidative stress as early event in neurodegeneration (2022)
- Oxidative stress precedes pathology in AD (2024)
- Oxidative damage in early AD (2023)
- Murphy, Mitochondrial ROS production (2023)
- Mitochondria and oxidative stress in neurons (2024)
- Finkel, Mitochondrial ROS in cell signaling (2023)
- ROS production in mitochondria (2024)
- Lin & Beal, Mitochondrial dysfunction in neurodegeneration (2024)
- Wallace, Mitochondrial DNA mutations in neurodegeneration (2023)
- Complex I deficiency in PD (2023)
- Cadenas & Davies, Mitochondrial ROS and aging (2024)
- Bedard & Krause, NOX family in brain (2023)
- NOX in neurodegeneration (2024)
- Lettre & Krause, NOX isoforms in neurons (2023)
- NOX2 in Alzheimer's disease (2024)
- NOX in Parkinson's disease (2023)
- NOX1 and alpha-synuclein (2024)
- NOX and neuroinflammation (2023)
- Brain iron homeostasis (2024)
- Copper in neurodegeneration (2023)
- Halliwell, Fenton chemistry in neurodegeneration (2024)
- Metals and amyloid-beta toxicity (2023)
- Iron in Parkinson's disease substantia nigra (2024)
- Ferritin in neurodegeneration (2023)
- Microglial ROS in neurodegeneration (2024)
- Nimmerjahn & Kirchhoff, Microglia in oxidative stress (2023)
- Microglia activation by A-beta (2024)
- Microglia and alpha-synuclein (2023)
- Ghezzi & Ziego, Antioxidant systems in brain (2024)
- Cellular antioxidant defenses (2023)
- Valentine & Hart, Superoxide dismutase isoforms (2024)
- SOD1 mutations in ALS (2023)
- Fridovich, Superoxide dismutase mechanism (2024)
- Arthur, Glutathione peroxidases (2023)
- Aoyama & Nakaki, Glutathione in neurodegeneration (2024)
- Mannervik, Glutathione reductase (2023)
- Pisoschi & Pop, Non-enzymatic antioxidants (2024)
- Brigelius-Flohe & Traber, Vitamin E function (2023)
- Vitamin E in AD and PD trials (2024)
- Rice, Ascorbate in brain (2023)
- Giacometti, CoQ10 in neurodegeneration (2024)
- CoQ10 in PD clinical trials (2023)
- Mares, Carotenoids and flavonoids in brain (2024)
- Lipid peroxidation in neurodegeneration (2024)
- 4-HNE in neurodegeneration (2023)
- Lipid peroxidation products (2024)
- Uchida, Protein adduction by lipid peroxides (2023)
- Lipid peroxidation in AD brain (2024)
- 4-HNE modifications in AD (2023)
- Lipid peroxidation and apoptosis (2024)
- Lipid peroxidation in PD substantia nigra (2023)
- Protein carbonylation in neurodegeneration (2024)
- Stadtman & Levine, Protein oxidation mechanisms (2023)
- Carbonyl formation in proteins (2024)
- Protein carbonyls in AD (2023)
- Oxidized proteins in neurodegeneration (2024)
- Glutamine synthetase oxidation in AD (2023)
- Oxidative DNA damage in neurodegeneration (2024)
- 8-oxoG in brain aging (2023)
- Krokan & Bjørklund, Base excision repair in brain (2024)
- DNA oxidation in early AD (2023)
- Coppedè & Migliore, DNA repair in AD (2024)
- Mitochondrial DNA mutations in PD (2023)
- Nunnari & Suomalainen, Mitochondria and oxidative stress loop (2024)
- Mitochondria and neurodegeneration (2023)
- Mitochondrial ROS and damage (2024)
- Schapira, Mitochondrial ATP production failure (2023)
- Mitochondrial permeability transition (2024)
- Apoptosis and mitochondria (2023)
- Antioxidant therapy in neurodegeneration (2024)
- Clinical trials of antioxidants in AD (2023)
- Vitamin E and cognitive decline (2024)
- Antioxidant supplementation risks (2023)
- Cai & Yan, Targeted antioxidant approaches (2024)
- NOX inhibitors in neurodegeneration (2023)
- Murphy & Smith, Mitochondria-targeted antioxidants (2024)
- Bush, Metal homeostasis and neurodegeneration (2023)
- Iron chelation in PD (2024)
- Bush & Curtain, Clioquinol in AD trials (2023)
- Johnson & Johnson, Nrf2 in neurodegeneration (2024)
- Nrf2 pathway functions (2023)
- Nrf2 activation in MS and neurodegeneration (2024)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.